HGF and sarcoma: For example, SST0001, a modified heparin, significantly reduces in vivo heparanase activity and controls levels of growth factors including HGF and VEGF, thereby preventing angiogenesis in human pediatric sarcoma models (Cassinelli et al., 2013).